The Success Rates From IVF are Nowhere Near What People Think
By Ellie Kincaid,
Business Insider [Australia]
| 05. 29. 2015
Untitled Document
“Test tube babies” are not that rare these days.
The Centres for Disease Control and Prevention estimates that 1.5% of babies born in the US are conceived using what’s called Assisted Reproductive Technology (ART), of which the most common procedure is in vitro fertilization (IVF).
IVF is a procedure in which eggs are taken from a woman’s ovaries and fertilised with sperm in a petri dish. Then one or more fertilised embryos are placed in the woman’s uterus, where one will hopefully implant and grow into a baby.
Though thousands of IVF cycles are done every year in the US, it’s tricky to get a sense of an individual woman’s chance of conceiving with the procedure. The graphs below, from the CDC, show exactly how often IVF resulted in a baby for women who went through the costly treatment using their own eggs, not donor eggs. A single IVF cycle costs an average of $US12,400, according to the American Society for Reproductive Medicine (ASRM), and women often need multiple tries to get pregnant.
About 36% of IVF...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...